Implementation Initiatives and Partners
Who is Rolling out PrEP Now, How are They Doing it & Who is Funding it
MOSAIC (Maximizing Options to Advance Informed Choice for HIV Prevention) is a five-year (2021-2026) global project funded by PEPFAR through USAID. Its goal is to accelerate the introduction and scale-up of new biomedical prevention products, primarily for women. MOSAIC will work across multiple countries to implement user-centered research to understand and remove barriers to new product introduction, access, and use; provide technical assistance to global, national, and subnational stakeholders to expedite product launch and scale-up; and strengthen the capacity of a wide range of local partners to perform essential functions that support the introduction of HIV prevention products. To learn more about MOSAIC, click here.
PROMISE and CHOICE
CHOICE (Collaboration for HIV Prevention Options to Control the Epidemic) and PROMISE (Preparing for Ring Opportunities through Market Introduction Support and Knowledge Exchange) are USAID-funded activities harnessing research utilization expertise to address technical gaps and scale up the use of PrEP (both oral PrEP and the monthly dapivirine vaginal ring) in sub-Saharan Africa. To read more about CHOICE’s work, download this overview. To read more about PROMISE and CHOICE work on the monthly dapivirine ring, download this overview. To see tools & resources related to these projects, click here.
OPTIONS and Other USAID Microbicide Product Introduction Initiative (MPii) Projects
The US Agency for International Development (USAID) is supporting five connected projects focused on introducing and providing access to ARV-based HIV prevention. These projects, which run from 2015-2020, focus on gender-based violence, drug resistance, creating demand, introducing new products, and models for delivering services. For a more detailed look at each of the five MPii projects, click here. And to see Tools & Resources from these projects, click here.
Launched in 2014, the DREAMS Initiative aims to reduce the incidence of HIV by 40 percent among adolescent girls and young women by 2020. It is a collaboration between the US President’s Emergency Plan for AIDS Relief (PEPFAR), the Bill & Melinda Gates Foundation, Girl Effect, Johnson & Johnson, Gilead Sciences and ViiV Healthcare.
The PEPFAR Scientific Advisory Board has endorsed PrEP and launched a DREAMS Innovation Challenge, to make more resources available for PrEP.
DREAMS is operating in ten countries, five of which have included PrEP for adolescent girls and young women in their country plans to address HIV.
PEPFAR (US President’s Emergency Plan for AIDS Relief)
Working in over 60 countries, PEPFAR has transformed the global HIV/AIDS response by supporting nearly 11.5 million people with antiretroviral treatment, a 50 percent increase since 2014. This is compared with the only 50,000 people who were on treatment in sub-Saharan Africa when PEPFAR began in 2003.
PEPFAR is now supporting rollout of PrEP. Click here to explore quarterly PEPFAR data, including the “number of adults and adolescents who received PrEP”. Click here to view PEPFAR “Country Operational Plans (COPs)” which outline PEPFAR yearly plans, country-by-country. Many COPs include provisions for PrEP.
Bridge to Scale (Jilinde)
The Bridge to Scale, or Jilinde, project is an implementation science initiative that seeks to move oral pre-exposure prophylaxis (PrEP) from research and demonstration settings into a large-scale public health response in Kenya. Over 20,000 people at highest risk of HIV infection will receive oral PrEP, which will be integrated within existing HIV combination prevention services. This project will demonstrate the incredible potential of PrEP and generate evidence that population-level PrEP interventions are feasible and effective in low-and middle-income countries, which bear the brunt of the world’s HIV burden. Bridge to Scale began delivering PrEP in early 2017.
The project functions as a learning laboratory to identify and document the barriers and enablers to PrEP uptake. Ultimately, the project will develop an affordable, effective, sustainable and replicable model for oral PrEP scale-up.
HIV Prevention Market Manager
Through the HIV Prevention Market Manager (PMM) Project, AVAC and CHAI seek to facilitate an efficient and effective rollout of HIV prevention products. The PMM works with partners across the prevention research to rollout spectrum to expand the portfolio of options and ensure appropriate products are available, accessible and used by those who need them most. For more information, a two-page document and an 18 slide summary document are available.
For resources on end user work to date, click here.